Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced new data that are expected to introduce significant, quantifiable time and cost savings into its clinical program for dengue fever.
Island Pharmaceuticals says new data leads to ISLA-101 Phase 2 study changes
June 3, 2024 Australian Biotech
Latest Video
New Stories
-
TGA approves first-of-a-kind medicine for early symptomatic Alzheimer’s disease
May 21, 2025 - - Latest News -
Examples are important as evidence of the problem, but be prepared to defend them
May 21, 2025 - - Latest News -
Trump administration invites companies to 'align' US pricing under MFN plan
May 21, 2025 - - Latest News -
NDIS minister restates the importance of 'nothing about us, without us!'
May 20, 2025 - - Latest News -
Industry alarm over the sudden pursuit of surprise uncertified claims
May 20, 2025 - - Latest News -
Medicines Australia sharpens post-election language on reform
May 20, 2025 - - Latest News -
Report highlights international confidence in Australian clinical trials
May 19, 2025 - - Latest News